Skip to main content

Gout

      Day 1 Recap at ACR24
      This is very true. We showed a number of years ago that patients with gout have increased platelet activation at baselin
      This is very true. We showed a number of years ago that patients with gout have increased platelet activation at baseline, which then dramatically increases during flare. Treating gout properly may ameliorate this. #ACR24 @RheumNow https://t.co/VL8fy3ezjx https://t.co/9XdrG1NG9c
      ACR Convergence 2024 opened today with a full slate of presentations, posters and specialty meetings.  The meeting began with a flip: the plenary sessions started at 9AM and the poster session…
      Challener et al. TriNetX study. 32,000 patients. SGLT2i reduce need for gout visits (HR 0.94) ULT initiation (HR 0.69) a
      Challener et al. TriNetX study. 32,000 patients. SGLT2i reduce need for gout visits (HR 0.94) ULT initiation (HR 0.69) and colchicine (HR 0.82). I worry about the discordant rates, ULT initiation much lower. @RheumNow #ACR24 Abstr#0848 https://t.co/VTKHMmDEKV https://t.co/C2opiDmBXx
      📈 Data from @UIowa_Rheum on how rurality impacts delay to diagnosis in #GCA

      📍 0747

      👉🏼 People living in mor
      1 month ago
      📈 Data from @UIowa_Rheum on how rurality impacts delay to diagnosis in #GCA 📍 0747 👉🏼 People living in more rural areas have an increased time to diagnosis & treatment- further prospective studies needed to delineate effects of rurality further @RheumNow #ACR24 @LemonReneeNi https://t.co/3YMcI9ha3T
      Yokose et al. Population study using NHANES. Gout patients had 1.6 higher fold risk of gallstone disease. What? Why do w
      Yokose et al. Population study using NHANES. Gout patients had 1.6 higher fold risk of gallstone disease. What? Why do we care? Well, GLP-1s associated with higher risk gallstones also... @RheumNow #ACR24 Abstr#0133 https://t.co/nf4R0hQe50 https://t.co/wDrEDeNbpT
      #ACR24 Year in Review:💡GLP1i significantly decreased knee OA pain over time (or was it the wt loss itself?🤨)💡

      #ACR24 Year in Review: 💡GLP1i significantly decreased knee OA pain over time (or was it the wt loss itself?🤨) 💡CD19 CAR T-Cell therapy has potential to treat/cure many autoimmune diseases (are risks and $ worth the benefit?) 💡 High risk of CV events within 30 days of gout… https://t.co/XF63zr6lk4 https://t.co/oRNri66Il9

      ×